GlaxoSmithKline New Year’s Resolutions Include Uping Commit Promotions
This article was originally published in The Tan Sheet
Executive Summary
A clinical study bolstering GlaxoSmithKline's campaign for Commit polacrilex lozenge, which targets smokers who have already tried other forms of nicotine replacement therapy, was released by the firm Jan. 2
You may also be interested in...
Glaxo NRT Promotional Campaign Targets Smokers Not Ready To Quit
GlaxoSmithKline is launching a $20 mil. ad campaign to boost the firm's lagging smoking cessation product sales following a disappointing second quarter performance
Nicotine Lozenge Underdosing Discouraged In GSK Smoking Cessation Study
Smokers should be encouraged to use at least seven to eight nicotine lozenges per day when attempting to quit smoking, researchers suggest in the June 10 Archives of Internal Medicine
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC